Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.11 +0.02 (0.07%) 5:28 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.11 +0.02 (0.07%) 5:28 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
by Zacks Equity Research
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
Q1 Earnings Drag Pharma ETFs Down
by Sweta Killa
Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.
Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings
by Swarup Gupta
The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).
Company News for May 2, 2018
by Zacks Equity Research
Companies In The News are: PFE,MRK,THC,BP
ADP Job Data, Q1 Earnings In Focus
by Zacks Equity Research
ADP Job Data, Q1 Earnings In Focus
Jobs Week Shows New Wage Growth (and Lack Thereof)
by Mark Vickery
Paychex reported small-business jobs and wage growth for last month, and the results are definitely interesting.
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.
Pfizer (PFE) Q1 Earnings Beat, Sales Miss, 2018 View Intact
by Kinjel Shah
Pfizer (PFE) beat expectations for earnings but missed the same for revenues in Q1. It retained its previously issued guidance for 2018.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
by Zacks Equity Research
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
Amazon (AMZN) Q1 Earnings Crush Estimates, Sales Surge Y/Y
by Zacks Equity Research
Amazon's (AMZN) first-quarter results benefit from robust revenue growth in the AWS segment.
Why Pfizer (PFE) Might Surprise This Earnings Season
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
by Zacks Equity Research
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .
What's in the Offing for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.
Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
by Zacks Equity Research
With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.
Is FlexShares Quality Dividend Defensive Index Fund (QDEF) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for QDEF
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
What's in the Cards for Merck (MRK) This Earnings Season?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer